China Pharma Holdings, Inc. (CPHI) P/E Ratio History
Deep ValueTrading at -1.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2006–2012
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, China Pharma Holdings, Inc. (CPHI) trades at a price-to-earnings ratio of -1.0x, with a stock price of $0.73 and trailing twelve-month earnings per share of $-0.83.
The current P/E is 100% below its 5-year average of 199.0x. Over the past five years, CPHI's P/E has ranged from a low of 54.8x to a high of 400.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, CPHI trades at a 104% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, CPHI trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CPHI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CPHI Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CPHI P/E vs Peers
Large-scale generic drug manufacturers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $311M | 13.1Lowest | -Best | -60% | |
| $90B | 19.4 | -Best | +49% | |
| $52B | 34.5 | -Best | +87%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CPHI Historical P/E Data (2006–2012)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2012 Q4 | Dec 31 2012 | $101.00 | $1.01 | 100.0x | -69% |
| FY2012 Q3 | Sep 30 2012 | $182.50 | $2.64 | 69.1x | -79% |
| FY2012 Q2 | Jun 30 2012 | $170.00 | $3.10 | 54.8x | -83% |
| FY2012 Q1 | Mar 31 2012 | $340.00 | $3.90 | 87.2x | -73% |
| FY2011 Q4 | Dec 31 2011 | $335.00 | $4.50 | 74.4x | -77% |
| FY2011 Q3 | Sep 30 2011 | $485.00 | $5.08 | 95.5x | -71% |
| FY2011 Q2 | - | $1125.00 | $5.72 | 196.7x | -39% |
| FY2011 Q1 | - | $1265.00 | $5.92 | 213.7x | -34% |
| FY2010 Q4 | Dec 31 2010 | $1515.00 | $5.82 | 260.3x | -20% |
| FY2010 Q3 | - | $1245.00 | $5.11 | 243.6x | -25% |
| FY2010 Q2 | Jun 30 2010 | $1375.00 | $5.41 | 254.2x | -22% |
| FY2010 Q1 | Mar 31 2010 | $1665.00 | $5.01 | 332.3x | +2% |
| FY2009 Q4 | - | $1925.00 | $4.81 | 400.2x | +23% |
| FY2009 Q3 | Sep 30 2009 | $1700.00 | $4.93 | 344.8x | +6% |
| FY2009 Q2 | - | $725.00 | $4.23 | 171.4x | -47% |
| FY2009 Q1 | - | $655.00 | $4.23 | 154.8x | -52% |
| FY2008 Q4 | Dec 31 2008 | $570.00 | $4.43 | 128.7x | -60% |
| FY2008 Q3 | - | $1040.00 | $4.18 | 248.8x | -23% |
| FY2008 Q2 | Jun 30 2008 | $1010.00 | $3.98 | 253.8x | -22% |
| FY2008 Q1 | Mar 31 2008 | $1150.00 | $3.88 | 296.4x | -9% |
| FY2007 Q4 | Dec 31 2007 | $1525.00 | $3.48 | 438.2x | +35% |
| FY2007 Q3 | Sep 30 2007 | $900.00 | $3.40 | 264.7x | -18% |
| FY2007 Q2 | Jun 30 2007 | $850.00 | $3.10 | 274.2x | -15% |
| FY2007 Q1 | Mar 31 2007 | $940.00 | $2.70 | 348.1x | +7% |
| FY2006 Q4 | Dec 31 2006 | $1135.00 | $2.50 | 454.0x | +40% |
| FY2006 Q3 | Sep 30 2006 | $700.00 | $1.91 | 366.5x | +13% |
| FY2006 Q2 | Jun 30 2006 | $685.00 | $0.26 | 2634.6x | +712% |
Average P/E for displayed period: 324.5x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CPHI — Frequently Asked Questions
Quick answers to the most common questions about buying CPHI stock.
What is CPHI's P/E ratio?
China Pharma Holdings, Inc. (CPHI) trailing twelve-month P/E ratio is -1.0x, based on TTM diluted EPS of $-0.83. The 5-year average P/E is 199.0x and the historical range spans 54.8x to 400.2x.
Is CPHI stock overvalued or undervalued?
CPHI trades at -1.0x P/E, below its 5-year average of 199.0x. At the 0th percentile of its historical range (54.8x–400.2x), the stock is priced at a discount to its own history.
Is CPHI stock expensive?
No, CPHI is not expensive on a historical basis. The current P/E of -1.0x is below the 5-year average of 199.0x and sits at the 0th percentile of its valuation range.
What is CPHI's historical P/E range?
Over the past 5 years, CPHI's P/E ratio has ranged from 54.8x to 400.2x, with a median of 213.7x and an average of 199.0x. The current P/E of -1.0x places the stock at the 0th percentile of this range. Full historical data spans 2006–2012.
How does CPHI's P/E compare to the S&P 500?
CPHI trades at -1.0x P/E versus the S&P 500 median of 24.3x. The 104% discount to the market suggests lower growth expectations or perceived higher risk.
How does CPHI's valuation compare to Healthcare peers?
China Pharma Holdings, Inc. P/E of -1.0x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CPHI's PEG ratio?
CPHI PEG ratio is N/A, based on a P/E of -1.0x and EPS growth of -174.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CPHI's earnings yield?
CPHI earnings yield is N/A, the inverse of its -1.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.